Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Van Buskirk

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|February 24, 2022
Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutritionSara J Hendrix, Patrick A Flume, Eric R First, et al.
BMC Cancer|December 10, 2014
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX studyPeter Gibbs, Val Gebski, Mark Van Buskirk, et al.
Cardiovascular and Interventional Radiology|November 1, 2011
Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approachRicarda Seidensticker, Max Seidensticker, Robert Damm, et al.
Eclinicalmedicine|March 2, 2026
Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trialLew Lim, Nazanin Hosseinkhah, Mark Van Buskirk, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 17, 2005
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysisJames E Goin, Riad Salem, Brian I Carr, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 17, 2005
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicitiesJames E Goin, Riad Salem, Brian I Carr, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 24, 2005
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imagingRobert J Lewandowski, Kenneth G Thurston, James E Goin, et al.
Gastroenterology|October 28, 2004
Yttrium-90 microspheres for the treatment of hepatocellular carcinomaJean Francois H Geschwind, Riad Salem, Brian I Carr, et al.
Clinical Colorectal Cancer|July 24, 2018
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled StudiesPeter Gibbs, Volker Heinemann, Navesh K Sharma, et al.
Hepatology (Baltimore, Md.)|November 22, 2013
Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolizationBenjamin Garlipp, Thierry de Baere, Robert Damm, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|February 24, 2022
Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutritionSara J Hendrix, Patrick A Flume, Eric R First, et al.
BMC Cancer|December 10, 2014
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX studyPeter Gibbs, Val Gebski, Mark Van Buskirk, et al.
Cardiovascular and Interventional Radiology|November 1, 2011
Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approachRicarda Seidensticker, Max Seidensticker, Robert Damm, et al.
Eclinicalmedicine|March 2, 2026
Photobiomodulation for cognitive dysfunction (Brain Fog) in post-COVID-19 condition: a randomized double-blind sham-controlled pilot trialLew Lim, Nazanin Hosseinkhah, Mark Van Buskirk, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 17, 2005
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysisJames E Goin, Riad Salem, Brian I Carr, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 17, 2005
Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicitiesJames E Goin, Riad Salem, Brian I Carr, et al.
Journal of Vascular and Interventional Radiology : JVIR|December 24, 2005
90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imagingRobert J Lewandowski, Kenneth G Thurston, James E Goin, et al.
Gastroenterology|October 28, 2004
Yttrium-90 microspheres for the treatment of hepatocellular carcinomaJean Francois H Geschwind, Riad Salem, Brian I Carr, et al.
Clinical Colorectal Cancer|July 24, 2018
Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled StudiesPeter Gibbs, Volker Heinemann, Navesh K Sharma, et al.
Hepatology (Baltimore, Md.)|November 22, 2013
Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolizationBenjamin Garlipp, Thierry de Baere, Robert Damm, et al.
Pageof 2